World’s Largest Gastrointestinal Cancer Congress to Highlight Advances and the Future of Care

BARCELONA, SPAIN (PRWEB) JUNE 08, 2017

What does the future hold for the prevention and care of patients with gastrointestinal cancers? The answer to this question and more will be highlighted from 28 June to 1 July at the ESMO 19th World Congress on Gastrointestinal Cancer (World GI Congress) in Barcelona, Spain. New research and discoveries on malignancies affecting every component of the gastrointestinal tract will be presented at this year’s Congress. The ESMO World Congress on Gastrointestinal Cancer, organized by Imedex, attracts more than 3,500 oncology professionals and researchers from around the globe.

"Set firmly within today’s context of precision medicine against cancer, this 19th edition of ESMO’s annual, leading World Congress on Gastrointestinal Cancer will represent an important step towards reversing the current global statistics ranking colorectal, liver and pancreatic cancers in 2nd, 4th and 7th place respectively, as those claiming the most deaths,” said Josep Tabernero, MD, PhD, Vice Chair of the Congress and President-elect of the European Society for Medical Oncology (ESMO).

Notable Keynote Lectures and Program Topics

The scientific agenda of the ESMO 19th World Congress on Gastrointestinal Cancer encompasses more than 85 presentations, including:

•     Liquid biopsies
•     The role of the microbiome in cancer medicine
•     Controversy debate: Hepatocellular carcinoma - Case scenarios
•     Controversy debate: Targeted agents versus PRRT in NET - Case scenarios
•     Understanding the relevant immune mechanisms in GI cancer

Abstracts to Be Released On-site at the World GI Congress

Upwards of 425 abstracts with studies spanning the spectrum of gastrointestinal cancer prevention and care were accepted for this year’s World GI Congress. Oral and late breaking abstracts selected by the Scientific Committee for presentation as part of the agenda are embargoed until the end of the scientific session during which they are presented. Oral abstracts scheduled for presentation include:

Wednesday, 28 June 2017

•     Survival analysis of patients with solid pseudopapillary tumors of the pancreas in a multicenter retrospective cohort – Brandon Huffman, et al., O-002
•     PEGPH20 Improves PFS in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Phase 2 Study in Combination With nab-Paclitaxel/Gemcitabine + – Andrew Hendifar, et al., O-003
•     Tumor Hyaluronan May Predict Benefit from PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA) – Andrew Hendifar, et al., O-028
•     Immunologic and Objective Tumor Responses to PEGylated Human IL-10 (AM0010) with 5- FU/LV and Oxaliplatin (FOLFOX) in Metastatic Pancreatic Adenocarcinoma (PDAC) – J. Randolph Hecht, et al., O-003

Thursday, 29 June 2017

•     Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky? – Hee Seok Moon, et al., O-005
•     Nivolumab Monotherapy in Patients with Advanced Gastric of Gastroesophageal Junction (GEJ) Cancer and 2 or More Prior Treatment Regimens: Sub-Analysis of the CheckMate 032 Study – Patrick Ott, et al., O-007
•     Efficacy and Safety of Nivolumab in Patients with Advanced Hepatocellular Carcinoma Analyzed by Patient Age: A Sub-Analysis of the CheckMate 040 Study – Ignacio Melero, et al., O-008
•     Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment – Jordi Bruix, et al., O-009

Friday, 30 June 2017

•     Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC) – Enrique Sanz-García, et al., O-010
•     RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC) – Filippo Pietrantonio, et al., O-011
•     Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial – Eric Van Cutsem, et al., O-012
•     Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients – Aparna Parikh, et al., O-001
•     The prognostic impact of primary tumor location in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis – Yuichi Goto, et al., O-013
•     Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by GONO – Emanuela Dell' Aquila, et al., O-014
•     Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status – Julien Taieb, et al., O-015
•     Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD – Ian Chau, et al., O-016
•     Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer – David Goldstein, et al., O-017
•     Molecular Variations Between Small Bowel Adenocarcinomas (SBAs), Right-Sided Colon Cancers (RT-Colon), and Gastroesophageal Cancers (GEC) – Mohamed Salem, et al., O-018
•     Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: a multi-disease phase 1 study – Hendrik-Tobias Arkenau, et al., O-019
•     Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma – Lipika Goyal, et al., O-020
•     Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs) – Stephanie Reyes, et al., O-021
•     Validation of Nu.Q™ colorectal cancer screening triage test to identify FIT positive individuals at low risk of screen relevant neoplasia – Mark Eccleston, et al., O-022
•     Mediterranean diet components are negatively associated with advanced colorectal polyps in a population-based case-control study – Naomi Fliss Isakov, et al., O-023
•     Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations? – Garry Mahon, et al., O-024

Saturday, 1 July 2017

•     Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall survival – Dominik Modest et al., O-029
•     FOLFOX4/XELOX in stage II-III colon cancer: Early survival data of the Italian Three or Six Colon Adjuvant (TOSCA) trial – Roberto Labianca, et al., O-025
•     Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study – Dominik Modest, et al., O-026
•     Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer – Guy van Hazel, et al., O-027

“True to the format and scope of meetings past, this superb Congress will also tackle other less common GI malignancies to which individual sessions have been allocated,” said Tabernero. “As Vice-Chair, I can promise the very latest findings that will help us to collectively advance our treatment strategies, novel approaches and selection of therapies in combination across various tumor types. Also under the lens will be the continued debate surrounding clinical trial design, relevance of results derived from a number of leading studies, the utility of benefit scales and the promise of emerging biosimilars. In addition, with cancer cases set to rise over the coming years, we will be delving into the epidemiology of disease and assessing the latest prevention strategies aimed at putting the brakes on these soaring statistics."

MEDIA RESOURCES

Media Registration

Members of the press will have the opportunity to interact with some of the world’s leading authorities in the study and treatment of gastrointestinal cancers. More than 70 experts from a range of disciplines will participate in the scientific program and their presentations will provide delegates with information on the latest developments in basic and clinical research. Their report on the expert discussion will bring the Congress to a close.

Press members may register using this link.

Journalists are required to submit appropriate media credentials as part of their registration application. Additional media information can be found on the Congress website under Press Information.

More Information About ESMO 19th World Congress on Gastrointestinal Cancer

Visit http://www.worldgicancer.com

About Imedex

Imedex is the industry leader in developing and delivering independent, accredited healthcare education. The Company’s programs specializing in oncology, hematology, and gastroenterology are provided through live events around the world as well as through effective online educational opportunities for on-the-go healthcare providers.

Imedex’s high-quality scientific programming translates the latest research into clinically relevant information. Our activities facilitate the needs of time-constrained healthcare professionals who are inundated by information through exceptional organization and outstanding educational value — all with a proven and sustained impact on patient care.

Imedex provides over 50,000 E-learning experiences annually and its live conferences have welcomed more than 100,000 attendees since 2001. The Company has a global footprint and operates in the United States, Europe, and Asia.

At Imedex, we believe education is the best medicine®. For more information on Imedex and upcoming conferences, visit us online at http://www.imedex.com, on our E-learning Center at http://elc.imedex.com, or via email at registration(at)imedex.com.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment. http://www.esmo.org

 Jordan Lasley Womens Jersey